Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Verici Dx Plc ( (GB:VRCI) ) has issued an announcement.
Verici Dx has reported that a peer-reviewed clinical validation study of its Pre-Transplant Rejection Assessment test has been published in Kidney360. The blood-based next-generation sequencing assay, marketed commercially by Thermo Fisher Scientific, is designed to assess early acute rejection risk in kidney transplant candidates before surgery.
According to the study, the PTRA test outperformed conventional risk assessment tools in predicting early acute rejection within the first two months post-transplant, allowing clinicians to identify low-risk patients who may safely receive reduced immunosuppressive therapy. Company executives and transplant specialists said the results support a more personalised approach to immunosuppression management, potentially reducing toxicity and infection risks while strengthening Verici Dx’s position in transplant diagnostics.
Spark’s Take on VRCI Stock
According to Spark, TipRanks’ AI Analyst, VRCI is a Neutral.
Verici Dx Plc’s overall stock score is driven by positive corporate events and technical indicators, which are offset by financial performance challenges and valuation concerns. The company’s strategic initiatives and market expansion efforts are promising, but ongoing profitability and cash flow issues present significant risks.
To see Spark’s full report on VRCI stock, click here.
More about Verici Dx Plc
Verici Dx plc is a precision diagnostics company focused on improving care for organ transplant patients. It uses multiomic analysis and proprietary artificial intelligence to develop predictive tests that help clinicians optimise therapy, guide biopsy decisions and stratify risk more accurately in complex transplant populations.
The company’s lead product, Tutivia, is a post-kidney transplant assay aimed at early detection of acute rejection. Headquartered in Cardiff in the UK and Franklin, Tennessee in the U.S., Verici Dx operates at the intersection of laboratory and data science, with tests validated in real-world, diverse patient cohorts to ensure clinical relevance and reliability.
Average Trading Volume: 1,317,837
Technical Sentiment Signal: Sell
Current Market Cap: £6.81M
See more insights into VRCI stock on TipRanks’ Stock Analysis page.